In STEP 4, people switched off semaglutide regained 6.9% of their weight within 48 weeks, while those who stayed on lost another 7.9%. In SURMOUNT-4, people switched off tirzepatide regained 14.0% within 52 weeks, while those who stayed on lost another 5.5%.1,2
After semaglutide: STEP 4
All 902 participants first took semaglutide for 20 weeks and lost 10.6% of their weight on average. The 803 who reached the full 2.4 mg dose were then split two to one: 535 stayed on semaglutide and 268 were switched to placebo, with a lifestyle program for both.1 From week 20 to week 68, weight changed by −7.9% on semaglutide and +6.9% on placebo. Waist size, blood pressure and physical functioning also did better with continued treatment. At the split, participants averaged 46 years of age and 107.2 kg, and 79% were women. Stomach and gut events were reported by 49.1% of those who stayed on semaglutide and 26.1% of those on placebo, and similar small shares stopped because of side effects, 2.4% and 2.2%.1
After tirzepatide: SURMOUNT-4
All 670 participants who finished a 36-week lead-in on tirzepatide had lost 20.9% of their weight. They averaged 48 years of age and 107.3 kg at the start, and 71% were women. They were then split between continuing tirzepatide and switching to placebo. From week 36 to week 88, weight changed by −5.5% on tirzepatide and +14.0% on placebo. At week 88, 89.5% of those still on tirzepatide had kept at least 80% of their earlier loss, against 16.6% of those on placebo.2
The placebo group did not go all the way back to the start within the trial. Across the full 88 weeks, weight was 9.9% below the starting point on placebo and 25.3% below on tirzepatide.2
Earlier evidence
The same pattern appeared with liraglutide, in a different design. In SCALE Maintenance, people who had lost at least 5% on a low-calorie diet kept that loss far more often on liraglutide than on placebo, 81.4% against 48.9%, over 56 weeks.3 Diet alone, without a drug, held the loss for only about half.
Why the labels say long term
The labels of Wegovy and Zepbound describe the aim as reducing excess body weight and maintaining the reduction long term, alongside a reduced-calorie diet and more physical activity.4,5 The withdrawal trials are the evidence behind that wording: the effect lasts while the medicine is taken.
The Wegovy label adds a caveat about its own withdrawal study. People who did not reach the 2.4 mg dose were not eligible for the randomized part, so the results may not reflect the experience of people just starting the medicine.4 The same applies to SURMOUNT-4, which split only people who completed the lead-in.2
In practice
- Stopping has a predictable result. Most of the benefit faded within a year in both trials.
- Gaps in coverage matter. If insurance ends, self-pay options can bridge the gap. Our page on GLP-1 costs without insurance lists them.
- Restarting means climbing again. After a long break the labels restart the dose climb at a lower step, to reduce stomach side effects.4
Limits
Both withdrawal trials stopped the drug abruptly and followed people for about a year afterwards. They do not show what a gradual taper or a lower maintenance dose would do, or what happens over several years.1,2 Our page on the Zepbound plateau covers the opposite situation: weight that stops falling while the drug continues.
Sources
- Rubino D, Abrahamsson N, Davies M, et al. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial. JAMA 2021;325:1414-1425. doi:10.1001/jama.2021.3224
- Aronne LJ, Sattar N, Horn DB, et al. Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity: the SURMOUNT-4 randomized clinical trial. JAMA 2024;331:38-48. doi:10.1001/jama.2023.24945
- Wadden TA, Hollander P, Klein S, et al. Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: the SCALE Maintenance randomized study. Int J Obes (Lond) 2013;37:1443-1451. doi:10.1038/ijo.2013.120
- WEGOVY (semaglutide) prescribing information, NDA 215256/S-025, revised June 2026. U.S. Food and Drug Administration; sections 1, 2 and 14. accessdata.fda.gov
- ZEPBOUND (tirzepatide) prescribing information, NDA 217806/S-041, revised August 2026. U.S. Food and Drug Administration; section 1. accessdata.fda.gov
Related analyses
Zepbound plateau: when weight loss slows, why, and what the trials show
GLP-1 cost without insurance: every manufacturer self-pay price, dose by dose
Switching from Wegovy to Zepbound: the starting dose, the timing, and what the evidence covers
Wegovy weight loss chart: the trial results week by week, in your own weight
Log your weight weekly, on and off treatment, and see the trend early.
Open Dose Insider